GlaxoSmithKline

GSK: 1,706.30 -7.90 (-0.46%) delayed: 19 Nov 2019, 8:01

Trade now

GlaxoSmithKline Fundamentals

Share Price Information

Name GlaxoSmithKline
Epic GSK
Sector Pharmaceuticals
ISIN GB0009252882
Activites GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn.
Index FTSE 100

Key numbers

Latest Share price (p) 1,706.30 Net gearing (%) 87.00
Market capitalisation (£m) 84,801.61 Gross gearing (%) 93.68
Shares in issue (m) 4,988.92 Debt ratio 89.68
P/E ratio 23.06 Debt-to-equity ratio 0.59
Total dividends per share (p) 80.00 Assets / equity ratio 15.81
Dividend yield (%) 4.71 Price to book value 23.09
Dividend cover 0.92 ROCE (%) 13.49
Earning per share (p) 73.70 EPS growth (%) 134.71
52-week high / low (p) 1,796.40 / 1,408.80 DPS growth (%) 0.00

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2018 Full Year 30,821 4,046 73.70 GBP
31 Dec 2017 Full Year 30,186 2,169 31.40 GBP
31 Dec 2016 Full Year 27,889 1,062 18.80 GBP

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year
H1 Dividend 08 Aug 2019 10 Oct 2019 19.00 GBX 0.00
Q1 Dividend 16 May 2019 11 Jul 2019 19.00 GBX 0.00
H2 Dividend 21 Feb 2019 11 Apr 2019 23.00 GBX 80.00
Q3 Dividend 15 Nov 2018 10 Jan 2019 19.00 GBX 0.00
H1 Dividend 09 Aug 2018 11 Oct 2018 19.00 GBX 0.00
Q1 Dividend 10 May 2018 12 Jul 2018 19.00 GBX 0.00
H2 Dividend 22 Feb 2018 12 Apr 2018 23.00 GBX 80.00
Q3 Dividend 09 Nov 2017 11 Jan 2018 19.00 GBX 0.00
H1 Dividend 10 Aug 2017 12 Oct 2017 19.00 GBX 0.00
Q1 Dividend 11 May 2017 13 Jul 2017 19.00 GBX 0.00
H2 Dividend 23 Feb 2017 13 Apr 2017 23.00 GBX 80.00
Q3 Dividend 03 Nov 2016 12 Jan 2017 19.00 GBX 0.00
H1 Dividend 11 Aug 2016 13 Oct 2016 19.00 GBX 0.00
Q1 Dividend 12 May 2016 14 Jul 2016 19.00 GBX 0.00
Special Dividend 18 Feb 2016 14 Apr 2016 20.00 GBX 0.00
H2 Dividend 18 Feb 2016 14 Apr 2016 23.00 GBX 80.00
Q3 Dividend 12 Nov 2015 14 Jan 2016 19.00 GBX 0.00
H1 Dividend 13 Aug 2015 01 Oct 2015 19.00 GBX 0.00
Q1 Dividend 14 May 2015 09 Jul 2015 19.00 GBX 0.00
H2 Dividend 19 Feb 2015 09 Apr 2015 23.00 GBX 80.00
Q3 Dividend 06 Nov 2014 08 Jan 2015 19.00 GBX 0.00

Contact details

Company name GlaxoSmithKline
Address 980 Great West Road, Brentford, Middlesex TW8 9GS.
Telephone +44 (0)20 8047 5000
Website http://www.gsk.com/

Advisors

Company's broker Jefferies Hoare Govett
Company's joint broker n/a
NOMAD n/a
Registrar Equiniti
Auditors PricewaterhouseCoopers LLP
Solicitors n/a

Directors

Appointed Director Position
01 Jan 2017 Emma Natasha Walmsley Chief Executive Officer
14 Jan 2019 Iain James Mackay Chief Financial Officer
01 Jan 2018 Dr Hal Barron Chief Scientific Officer
01 Sep 2019 Jonathan Richard Symonds Non-Executive Chairman
01 Jul 2012 Lynn Laverty Elsenhans Non-Executive Director
01 Sep 2017 Dr Laurie Hollis Glimcher Non-Executive Director
01 Jan 2016 Dr Jesse Goodman Non-Executive Director
01 Jan 2015 Urs Rohner Non-Executive Director
01 Apr 2011 Judith Carol Lewent Non-Executive Director
01 Jul 2016 Dr Vivienne Cox Non-Executive Director
01 Sep 2015 Manvinder Singh Banga Non-Executive Director

Company financials

Assets (£m) 2018 2017 2016
Reporting date 31 Dec 2018 31 Dec 2017 31 Dec 2016
Tangible assets 11,058 10,860 10,808
Intangible asssets and goodwill 22,991 23,296 24,741
Investments and other non-current assets 7,090 6,318 6,821
Total non-current assets 41,139 40,474 42,370
Inventory / work in progress 5,476 5,557 5,102
Trade and other receivables 6,423 6,000 6,026
Cash and equivalents 3,874 3,833 4,897
Other current assets and asset held for resale 1,154 517 686
Total of all assets 58,066 56,381 59,081
Liabilities (£m) 2018 2017 2016
Short term liabilities 22,491 26,569 19,001
Long term liabilities 31,903 26,323 35,117
Other liabilites / pension etc 0 0 0
Total of all liabilities 54,394 52,892 54,118
Net assets (£m) 2018 2017 2016
Net assets 3,672 3,489 4,963
Equity (£m) 2018 2017 2016
Share capital 1,345 1,343 1,342
Minority interests -688 3,557 3,839
Retained earnings -2,137 -6,477 -5,392
Share premium account 3,091 3,019 2,954
Other equity 2,061 2,047 2,220
Total equity 3,672 3,489 4,963
Cash Flow (£m) 2018 2017 2016
Cash from operating activities 8,421 6,918 6,497
Cashflow before financing 6,868 5,475 5,228
Increase / decrease in Cash 479 -905 -1,164
Income (£m) 2018 2017 2016
Turnover 30,821 30,186 27,889
Cost of sales 10,241 10,342 9,290
Gross profit 20,580 19,844 18,599
Operating profit 5,483 4,087 2,598
Pre-tax profit 4,800 3,525 1,939
Profit / loss for the year 4,046 2,169 1,062